Background
Methods
Patients
Histopathological analysis and immunohistochemistry (IHC)
MUC4 validation cohort
Statistical analysis
Results
IMPC is associated with poor outcome in HER2-positive breast cancer patients
Characteristic |
N° patients | % | Median | Range |
---|---|---|---|---|
Total number of patients | 86 | |||
Age (years) | 50 | 25–79 | ||
Length follow-up (months) | 30 | 6–112 | ||
Menopausal status | ||||
Pre | 48 | 55.8 | ||
Post | 38 | 44.2 | ||
Tumor size | ||||
T1 | 33 | 38.8 | ||
T2 | 36 | 42.4 | ||
T3 | 12 | 14.1 | ||
T4 | 4 | 4.7 | ||
Not documented | 1 | |||
Lymph node status | ||||
N0 | 44 | 51.2 | ||
N1 | 30 | 34.9 | ||
N2 | 5 | 5.8 | ||
N3 | 7 | 8.1 | ||
Clinical stage | ||||
I | 25 | 29.1 | ||
II | 40 | 46.5 | ||
III | 21 | 24.4 | ||
Histological grade | ||||
1 | 7 | 8.9 | ||
2 | 28 | 35.4 | ||
3 | 44 | 55.7 | ||
Not documented | 7 | |||
Estrogen receptor positive | 66.3 | |||
Progesterone receptor positive | 55.8 |
Clinicopathological characteristics | non-IMPC | IMPC |
P
| |
---|---|---|---|---|
n (%) |
n (%) | |||
Menopausal status | pre | 35 (50.0) | 13 (81.3) |
0.021
|
post | 35 (50.0) | 3 (18.8) | ||
Tumor size | 1 | 31 (44.9) | 2 (12.5) |
0.014
|
2–4 | 38 (55.1) | 14 (87.5) | ||
Lymph node status | 0 | 39 (55.7) | 5 (31.3) | 0.068 |
1–3 | 31 (44.3) | 11 (68.7) | ||
Clinical stage | I, II | 52 (74.3) | 13 (81.3) | 0.41 |
III | 18 (25.7) | 3 (18.7) | ||
Histological grade | 1,2 | 30 (46.2) | 5 (35.7) | 0.447 |
3 | 35 (53.8) | 9 (64.3) | ||
Estrogen receptor | Negative | 27 (38.6) | 2 (12.5) |
0.04
|
Positive | 43 (61.4) | 14 (87.5) | ||
Progesterone receptor | Negative | 33 (47.1) | 5 (31.3) | 0.248 |
Positive | 37 (52.9) | 11 (68.7) |
MUC4 is overexpressed in IMPC
MUC4 | non-IMPC | IMPC |
P
|
---|---|---|---|
n (%) |
n (%) | ||
Negative | 31 (44.3) | 0 (0) |
0.0003
|
Positive | 39 (55.7) | 16 (100) |
Expression of MUC4 and IMPC | ||||
---|---|---|---|---|
Age (years) | MUC4 negative | MUC4 positive/IMPC negative | MUC4 positive/IMPC positive |
P
|
< 50 | 13 (42.0) | 22 (56.4) | 13 (81.3) |
0.036
|
≥50 | 18 (58.0) | 17 (43.6) | 3 (18.7) |